

Shu Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9801065/publications.pdf>

Version: 2024-02-01

22
papers

459
citations

759233

12
h-index

752698

20
g-index

22
all docs

22
docs citations

22
times ranked

458
citing authors

#	ARTICLE	IF	CITATIONS
1	Formononetin attenuates atherosclerosis via regulating interaction between KLF4 and SRA in apoE ^{-/-} mice. <i>Theranostics</i> , 2020, 10, 1090-1106.	10.0	66
2	Inhibition of Vascular Calcification. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2382-2395.	2.4	41
3	Tectorigenin attenuates diabetic nephropathy by improving vascular endothelium dysfunction through activating AdipoR1/2 pathway. <i>Pharmacological Research</i> , 2020, 153, 104678.	7.1	40
4	Functional interplay between liver X receptor and AMP-activated protein kinase \pm inhibits atherosclerosis in apolipoprotein E-deficient mice \hat{a} a new anti-atherogenic strategy. <i>British Journal of Pharmacology</i> , 2018, 175, 1486-1503.	5.4	39
5	Formononetin ameliorates cholestasis by regulating hepatic SIRT1 and PPAR \pm . <i>Biochemical and Biophysical Research Communications</i> , 2019, 512, 770-778.	2.1	33
6	ERK1/2 inhibition reduces vascular calcification by activating miR-126-3p-DKK1/LRP6 pathway. <i>Theranostics</i> , 2021, 11, 1129-1146.	10.0	31
7	LongShengZhi Capsule reduces carrageenan-induced thrombosis by reducing activation of platelets and endothelial cells. <i>Pharmacological Research</i> , 2019, 144, 167-180.	7.1	29
8	Astragalus Flavone Ameliorates Atherosclerosis and Hepatic Steatosis Via Inhibiting Lipid-Disorder and Inflammation in apoE ^{-/-} Mice. <i>Frontiers in Pharmacology</i> , 2020, 11, 610550.	3.5	23
9	NaoXinTong Capsules inhibit the development of diabetic nephropathy in db/db mice. <i>Scientific Reports</i> , 2018, 8, 9158.	3.3	21
10	Metformin attenuates atherosclerosis and plaque vulnerability by upregulating KLF2-mediated autophagy in apoE ^{-/-} mice. <i>Biochemical and Biophysical Research Communications</i> , 2021, 557, 334-341.	2.1	18
11	Targeting macrophage liver X receptors by hydrogel-encapsulated T0901317 reduces atherosclerosis without effect on hepatic lipogenesis. <i>British Journal of Pharmacology</i> , 2021, 178, 1620-1638.	5.4	17
12	Tectorigenin alleviates intrahepatic cholestasis by inhibiting hepatic inflammation and bile accumulation via activation of PPAR β . <i>British Journal of Pharmacology</i> , 2021, 178, 2443-2460.	5.4	15
13	Calycosin ameliorates atherosclerosis by enhancing autophagy via regulating the interaction between KLF2 and MLKL in apolipoprotein E gene-deleted mice. <i>British Journal of Pharmacology</i> , 2022, 179, 252-269.	5.4	14
14	MicroRNA-193b impairs muscle growth in mouse models of type 2 diabetes by targeting the PDK1/Akt signalling pathway. <i>Diabetologia</i> , 2022, 65, 563-581.	6.3	11
15	KLF10 promotes nonalcoholic steatohepatitis progression through transcriptional activation of zDHHC7. <i>EMBO Reports</i> , 2022, 23, e54229.	4.5	11
16	Therapeutic potential of NaoXinTong Capsule on the developed diabetic nephropathy in db/db mice. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109389.	5.6	10
17	Danthron ameliorates obesity and MAFLD through activating the interplay between PPAR \pm /RXR \pm heterodimer and adiponectin receptor 2. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111344.	5.6	10
18	Teniposide regulates the phenotype switching of vascular smooth muscle cells in a miR-21-dependent manner. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 1040-1046.	2.1	9

#	ARTICLE	IF	CITATIONS
19	Pterostilbene Alleviates Cholestasis by Promoting SIRT1 Activity in Hepatocytes and Macrophages. <i>Frontiers in Pharmacology</i> , 2021, 12, 785403.	3.5	8
20	Inhibition of Podocytes DPP4 Activity Is a Potential Mechanism of Lobeliae Chinensis Herba in Treating Diabetic Kidney Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 779652.	3.5	8
21	Impaired regulation of MMP2/16â€“MLCK3 by miR-146a-5p increased susceptibility to myocardial ischaemic injury in aging mice. <i>Cardiovascular Research</i> , 2023, 119, 786-801.	3.8	3
22	Combination of MEK1/2 inhibitor and LXR ligand synergistically inhibit atherosclerosis in LDLR deficient mice. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 512-517.	2.1	2